Ab. Sarmento et al., PARTITION OF DOPAMINE ANTAGONISTS INTO SYNTHETIC LIPID BILAYERS - THEEFFECT OF MEMBRANE-STRUCTURE AND COMPOSITION, Journal of Pharmacy and Pharmacology, 45(7), 1993, pp. 601-605
Partition coefficients, K(p), of four dopamine antagonists (pimozide,
fluspirilene, haloperidol and domperidone) between the aqueous phase a
nd lipid bilayer vesicles were determined as a function of lipid chain
length, unsaturation and temperature encompassing the range of the li
pid phase transition. Model membranes of egg phosphatidylcholine (PC),
dimyristoyl (DMPC)-, dipalmitoyl (DPPC)-, distearoyl (DSPC)- and diol
eoyl (DOPC)-phosphatidylcholines were studied. K(p) values of the drug
s are different in the various membranes under study and depend on tem
perature, aliphatic carbon chain-length and on the presence of unsatur
ation in the aliphatic lipid chain. First-order transition of membrane
lipids from the gel to the liquid crystalline state is accompanied by
a sharp increase of the partition coefficient of pimozide and fluspir
ilene in DMPC, DPPC and DSPC bilayers. For domperidone, K(p) values ar
e maximal within the mid-point of phase transition of DMPC and DPPC, w
hile for DSPC K(p) values increase progressively with increasing tempe
rature. Haloperidol K(p) values display a maximum at the mid-point of
phase transition of DMPC, while a progressive increase of K(p) is obse
rved in DPPC and DSPC. The four drugs are easily accommodated in bilay
ers of short aliphatic chain lipids (DMPC), the partition coefficients
being 17 137 for pimozide, 18 700 for fluspirilene, 686 for domperido
ne and 722 for haloperidol, at temperatures 10-degrees-C below the mid
-point of the lipid phase transition. Except for haloperidol, the part
ition of the drugs in DOPC (18:1) is higher than that in DSPC (18:0) b
ilayers at a temperature above the phase transition temperature of bot
h lipids. From our experiments we can conclude that artificial membran
es are useful models to understand the physicochemical mechanisms invo
lved in the interaction of dopamine antagonists with biological membra
nes.